European Medicines Agency, 18/05/2018 The European Medicines Agency (EMA) is evaluating preliminary results from a study which found 4 cases of birth defects such as spina bifida (malformed spinal cord) in babies born to mothers who became pregnant while taking dolutegravir. While EMA is assessing the new evidence it has issued the following precautionary advice: Dolutegravir HIV medicines should...
aidsmap/nam, 25 October 2016
SImplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug regimen, researchers reported on Monday at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).
Read more here